Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker.
about
Down syndrome and leukemia: insights into leukemogenesis and translational targetsGATA factor mutations in hematologic disease.Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome.Gene expression changes associated with progression and response in chronic myeloid leukemia.Integrated differential transcriptome maps of Acute Megakaryoblastic Leukemia (AMKL) in children with or without Down Syndrome (DS)The use of mouse models for understanding the biology of down syndrome and agingDifferential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.Origins of leukaemia in children with Down syndrome.Use of gene expression microarrays for the study of acute leukemia.Hematopoietic disorders in Down syndromePerturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorderDevelopment of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes.Malignancy in children with trisomy 21.The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.Leukocytosis in an infant with Down syndrome.Stem and progenitor cell dysfunction in human trisomies.Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice.
P2860
Q26770335-EDB4D2A8-CAC7-4A97-AAE4-A9FC89260B8EQ33439175-ABC5B551-CFF4-42BA-BED1-2CC49939A23FQ34430274-F7430123-F883-4307-A193-50505ACA3A52Q34479561-A8B3F6D8-DD4D-4AE2-8E49-ECCD9831ECD4Q35005153-1081F029-3A77-45F0-9495-2FCFF07B60E6Q35810481-2E8E8CD3-19AD-4693-8F9D-0A8393A55879Q35848677-475C514E-B79D-46FB-AEBA-01BF7F385649Q35998756-202EAB15-53CB-4CC9-8603-97980878418CQ36607291-08FA1050-7C52-487D-B06E-3D35229A1171Q36784955-657C6D76-3D59-4967-9D17-503BAAD1724BQ37083967-A6D2567B-FC6F-4F5A-A69A-B4ECFB7F0AB4Q37215179-55FBBAA1-6E86-46D0-A747-FAF5674736F2Q37379570-3EB2D4D8-A384-4AA6-A1EA-40975CEA2828Q37381700-1FCC6E00-6D30-4C60-A95D-3E3F505177B3Q38198542-157AD50E-E4F2-4103-8527-B3038A3E9C82Q38292512-A5D8266C-9E92-446F-ADB8-B842AA36108AQ53773428-D462F6E5-1FAB-4744-A534-066F635F6DFB
P2860
Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Microarray transcript profilin ...... pecific discriminating marker.
@en
Microarray transcript profilin ...... pecific discriminating marker.
@nl
type
label
Microarray transcript profilin ...... pecific discriminating marker.
@en
Microarray transcript profilin ...... pecific discriminating marker.
@nl
prefLabel
Microarray transcript profilin ...... pecific discriminating marker.
@en
Microarray transcript profilin ...... pecific discriminating marker.
@nl
P2093
P2860
P1476
Microarray transcript profilin ...... specific discriminating marker
@en
P2093
Afua Mensah
Andrea Rinaldi
Chiara Baldo
Claire Mulligan
Dean Nizetic
Finbarr E Cotter
Franca Dagna-Bricarelli
Gareth Denyer
Jürgen Groet
P2860
P304
P356
10.1111/J.1365-2141.2004.04982.X
P407
P577
2004-06-01T00:00:00Z